These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17620360)

  • 1. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.
    Hislop AD; Ressing ME; van Leeuwen D; Pudney VA; Horst D; Koppers-Lalic D; Croft NP; Neefjes JJ; Rickinson AB; Wiertz EJ
    J Exp Med; 2007 Aug; 204(8):1863-73. PubMed ID: 17620360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
    PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
    Horst D; van Leeuwen D; Croft NP; Garstka MA; Hislop AD; Kremmer E; Rickinson AB; Wiertz EJ; Ressing ME
    J Immunol; 2009 Feb; 182(4):2313-24. PubMed ID: 19201886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
    Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
    PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
    Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
    Jochum S; Moosmann A; Lang S; Hammerschmidt W; Zeidler R
    PLoS Pathog; 2012; 8(5):e1002704. PubMed ID: 22615564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
    Quinn LL; Williams LR; White C; Forrest C; Zuo J; Rowe M
    J Virol; 2016 Jan; 90(1):356-67. PubMed ID: 26468525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
    Ressing ME; Keating SE; van Leeuwen D; Koppers-Lalic D; Pappworth IY; Wiertz EJ; Rowe M
    J Immunol; 2005 Jun; 174(11):6829-38. PubMed ID: 15905524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.
    Zuo J; Currin A; Griffin BD; Shannon-Lowe C; Thomas WA; Ressing ME; Wiertz EJ; Rowe M
    PLoS Pathog; 2009 Jan; 5(1):e1000255. PubMed ID: 19119421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.
    Bell MJ; Abbott RJ; Croft NP; Hislop AD; Burrows SR
    J Virol; 2009 Mar; 83(6):2783-8. PubMed ID: 19129449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.
    Steven NM; Annels NE; Kumar A; Leese AM; Kurilla MG; Rickinson AB
    J Exp Med; 1997 May; 185(9):1605-17. PubMed ID: 9151898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.
    Horst D; Burrows SR; Gatherer D; van Wilgenburg B; Bell MJ; Boer IG; Ressing ME; Wiertz EJ
    J Virol; 2012 Jan; 86(1):572-7. PubMed ID: 22013037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail.
    Griffin BD; Gram AM; Mulder A; Van Leeuwen D; Claas FH; Wang F; Ressing ME; Wiertz E
    J Immunol; 2013 Feb; 190(4):1672-84. PubMed ID: 23315076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A11 Tetramer-assisted characterization of Rta-specific CD8+ T-cell responses in healthy virus carriers.
    Yu HX; Srinivasan N; Ren EE; Chan SH
    Tissue Antigens; 2005 Jun; 65(6):539-43. PubMed ID: 15896201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R; Burrows SR; Moss DJ; Silins SL
    J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
    Strong MJ; Laskow T; Nakhoul H; Blanchard E; Liu Y; Wang X; Baddoo M; Lin Z; Yin Q; Flemington EK
    J Virol; 2015 Oct; 89(19):10110-4. PubMed ID: 26178981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
    Serafini B; Rosicarelli B; Veroni C; Mazzola GA; Aloisi F
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.